AstraZeneca PLC (AZN) Stock

About AstraZeneca PLC

AstraZeneca PLC is led by CEO Pascal Claude Roland Soriot, employs 94,300 people, headquartered in Cambridge, GB, publicly traded since 1993.

AstraZeneca PLC (AZN) stock trades at $165.41 with a market capitalization of $256.53B. The stock is valued at a price-to-earnings (P/E) ratio of 24.77, price-to-book of 5.10, price-to-sales of 4.21. Over the past 52 weeks the stock has ranged between $146.10 and $212.71, and currently trades 22.2% below its 52-week high. It pays a dividend yielding 1.27%.

On profitability, AstraZeneca PLC generates a return on equity (ROE) of 21.68%, above the typical market range of roughly 12-15%, return on capital employed of 16.41%, an operating margin of 23.28%, a net profit margin of 17.02%.

In its most recent fiscal year, AstraZeneca PLC reported annual revenue of $58.7B, net profit of $10.3B. Over the last 5 fiscal years, revenue grew at an average annual rate of 17.2%, and net profit grew at an average annual rate of 26.3%. Over that span net profit grew faster than revenue, so net margin widened.

The balance sheet shows a debt-to-equity ratio of 0.64, a current ratio of 0.94, total assets of $114.1B, $5.7B in cash and equivalents.

AZN has an average daily trading volume of 3,091,897 shares, a beta of 0.21 (historically less volatile than the overall market).